“Researchers have studied the effects of nicotinamide, a form of vitamin B3, on animal and cell models for glaucoma. Their study may be a future neuroprotective therapy in glaucoma in humans. A clinical trial will start later this year.” [Source: Medicalexpress.com]
Often referred to as the ‘silent thief’ of sight, glaucoma refers to a group of eye diseases that develop as a result of elevated intraocular pressure inside the eye. This increased pressure damages the optic nerve and can cause vision loss. Conventional medicine treats glaucoma with chemical eye drops and drugs, laser surgery, traditional surgery, or a combination of these.
With estimates putting the total number of suspected cases at over 60 million globally, glaucoma is a major cause of blindness. The number of people affected is expected to increase to more than 111 million by 2040, disproportionally affecting people residing in Asia and Africa.
The Cellular Medicine approach to preventing and controlling glaucoma is based on providing an optimum supply of essential micronutrients to the cells of the eye and its various anatomical components. The most important micronutrients for protecting the eyes include vitamins C, A and E; the amino acids arginine and cysteine; alpha lipoic acid; lutein and other carotenoids; and polyphenols such as those obtained from grape seeds. These micronutrients should be taken in addition to following Dr. Rath’s Basic Cellular Health Recommendations.
To learn more about the Cellular Medicine approach to preventing and controlling common eye diseases, see this article on our website.